Jubiliant Org to market nuclear medicine in Europe

Draximage Ltd, a subsidiary of the integrated pharmaceutical industry player Jubilant Organosys Ltd, announced on Thursday that it has signed an agreement with France based Guerbet for the distribution of its nuclear medicine products in Europe, the company said in a BSE filing.

Draximage specialises in radiopharmaceuticals business and Guerbet is a leading medical imaging player in Europe. The partnership agreement will provide a springboard to Draximage to extend the reach of its nuclear medicine products in the European markets including Germany, France, UK, Italy and Spain.

With the partnership Guerbet will become the exclusive distributor for the sale of Draximage range of products including, Sestamibi, I-131, MDP DTPA and MAA, through its network of European subsidiaries.

This will facilitate easy availability of these nuclear medicines which are much in demand by the medical professionals in the emerging markets due to the rapid development of hybrid technologies (nuclear medicine and MRI, nuclear medicine and scanners).